SPR741

Synonym(s): NAB741

Class: Polymyxin

Details of activity:	Disrupts the outer membrane by direct interaction with the lipid A component of the LPS and and disrupts the physical integrity of the phospholipid bilayer of the inner membrane, and possibly additional modes of action.
Combined with other compounds:	Yes
Description:	Potentiates the activity of rifampin, clarithromycin, azithromycin, mupirocin, fusidic acid and vancomycin against E. coli, K. pneumoniae and A. baumannii but not P. aeruginosa.
Institute where first reported:	Northern Antibiotics, Spero Therapeutics
Highest developmental phase:	Phase 1
Development status:	Discontinued
Reason Dropped:	Replaced by SPR206; develoiped instead as an antibiotic adjuvant

Chemical structure(s):
Canonical SMILES:	CC(C)C[C@H]1C(=O)N[C@@H](CCN)C(=O)N[C@@H](CCN)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC[C@@H](C(=O)N[C@@H](CCN)C(=O)N[C@H](CC2=CC=CC=C2)C(=O)N1)NC(=O)[C@@H](CO)NC(=O)[C@H]([C@@H](C)O)NC(=O)C
Isomeric SMILES:	C[C@H]([C@H]1C(=O)NCC[C@@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N1)CCN)CCN)CC(C)C)CC2=CC=CC=C2)CCN)NC(=O)[C@@H](CO)NC(=O)[C@H]([C@@H](C)O)NC(=O)C)O
InChI:	InChI=1S/C44H73N13O13/c1-22(2)19-31-40(66)52-27(11-15-45)36(62)51-29(13-17-47)39(65)57-34(23(3)59)43(69)48-18-14-30(53-42(68)33(21-58)56-44(70)35(24(4)60)49-25(5)61)38(64)50-28(12-16-46)37(63)55-32(41(67)54-31)20-26-9-7-6-8-10-26/h6-10,22-24,27-35,58-60H,11-21,45-47H2,1-5H3,(H,48,69)(H,49,61)(H,50,64)(H,51,62)(H,52,66)(H,53,68)(H,54,67)(H,55,63)(H,56,70)(H,57,65)/t23-,24-,27+,28+,29+,30+,31+,32-,33-,34+,35+/m1/s1
InChI Key:	JBFNEVNUGGFPBQ-DDMCRLCFSA-N
Structure link:	https://pubchem.ncbi.nlm.nih.gov/compound/53323381

External links:
Guide to Pharmacology:	SPR741
Citations:	https://www.ncbi.nlm.nih.gov/pubmed/28533232 https://www.ncbi.nlm.nih.gov/pubmed/28947471 https://www.ncbi.nlm.nih.gov/pubmed/29914941